Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug–Drug Interactions with a Novel Series of Centrally Efficacious BACE1 InhibitorsMichael A. Brodney, Brian T. O’Neill, Elizabeth M. Beck et al.|Journal of Medicinal Chemistry|2015Cited by 78
Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitorsAndrea M. Zuhl, Douglas S. Johnson, Claude Ambroise et al.|Nature Communications|2016Cited by 77
Discovery of a Series of Efficient, Centrally Efficacious BACE1 Inhibitors through Structure-Based Drug DesignChristopher R. Butler, Brian T. O’Neill, Michael A. Brodney et al.|Journal of Medicinal Chemistry|2015Cited by 46
Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide FunctionalityChristopher R. Butler, Michael A. Brodney, Kevin Ogilvie et al.|Journal of Medicinal Chemistry|2016Cited by 45
Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking HypopigmentationBrian T. O’Neill, Michael A. Brodney, Elizabeth M. Beck et al.|Journal of Medicinal Chemistry|2018Cited by 42